天津力生制药股份有限公司 关于使用闲置自有资金进行现金管理的进展公告

Core Viewpoint - The company has approved the use of up to RMB 1 billion of idle funds for cash management through the purchase of short-term financial products, ensuring safety and liquidity [1] Group 1: Cash Management Details - The company has invested a total of RMB 210 million in financial products issued by Bohai Bank [1] - The investment is part of a broader approval for cash management activities, which includes the use of idle funds for financial products with a maturity of no more than 12 months [1] Group 2: Related Party Transactions - Bohai Bank, where the company has invested, is a related party as the company's indirect controlling shareholder holds 20.34% of its shares [1] - The bank's registered capital is RMB 1,776.2 million, with total assets of RMB 1,905.876 billion and liabilities of RMB 1,792.743 billion as of September 30, 2025 [1] Group 3: Risk Control Measures - The company aims to manage risks by investing in high-safety, liquid short-term financial products issued by major banks or securities institutions [3] - The finance department is responsible for managing these investments and monitoring any potential risks [3] - Regular audits and checks will be conducted by the audit department and independent directors to ensure compliance and safety of the investments [3] Group 4: Impact on the Company - The cash management strategy is designed to enhance fund utilization efficiency without affecting the company's daily operations or core business development [4] - This approach is expected to yield certain investment returns, thereby improving overall performance and safeguarding shareholder interests [4] Group 5: Historical Cash Management Activities - Over the past twelve months, the company has utilized a total of RMB 800 million for cash management, which remains within the authorized limits set by the shareholders' meeting [5]